Chang Chun-Wei, Yang Shieh-Yueh, Yang Che-Chuan, Chang Chia-Wen, Wu Yih-Ru
Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
MagQu Co. Ltd., New Taipei City, Taiwan.
Front Neurol. 2020 Jan 21;10:1388. doi: 10.3389/fneur.2019.01388. eCollection 2019.
Parkinson's disease (PD) is the second most common neurodegenerative disease, and α-synuclein plays a critical role in the pathogenesis of PD. Studies have revealed controversial results regarding the correlation between motor severity and α-synuclein levels in peripheral blood from patients with PD. We examined α-synuclein levels in plasma or serum in patients with PD and investigated the relationship between plasma or serum α-synuclein level and motor symptom severity. We recruited 88 participants (48 patients with PD and 40 healthy controls). Clinical information was collected, and venous blood was drawn from each participant to be processed to obtain plasma or serum. The plasma or serum α-synuclein level was detected using monoclonal antibodies with magnetic nanoparticles, and was measured through immunomagnetic reduction. Plasma or serum α-synuclein levels were quantitatively detected. In patients with PD, the means of plasma and serum α-synuclein level were 3.60 ± 2.53 and 0.03 ± 0.04 pg/mL, respectively. The areas under the receiver operating characteristic curve of plasma and serum α-synuclein for distinguishing patients with PD from healthy controls were 0.992 and 0.917, respectively. The serum α-synuclein level also showed a significant correlation with patients in H-Y stages 1-3 ( = 0.40, = 0.025), implying that the serum α-synuclein level may be a potential marker of motor symptom severity in patients with early PD. Our data suggest that the α-synuclein level in serum or plasma can differentiate between healthy controls and patients with PD. Serum α-synuclein levels moderately correlate with motor severity in patients with early PD.
帕金森病（PD）是第二常见的神经退行性疾病，α-突触核蛋白在PD的发病机制中起关键作用。关于PD患者外周血中运动严重程度与α-突触核蛋白水平之间的相关性，研究得出了相互矛盾的结果。我们检测了PD患者血浆或血清中的α-突触核蛋白水平，并研究了血浆或血清α-突触核蛋白水平与运动症状严重程度之间的关系。我们招募了88名参与者（48例PD患者和40名健康对照）。收集临床信息，并从每位参与者采集静脉血进行处理以获得血浆或血清。使用带有磁性纳米颗粒的单克隆抗体检测血浆或血清α-突触核蛋白水平，并通过免疫磁珠法进行测量。对血浆或血清α-突触核蛋白水平进行定量检测。在PD患者中，血浆和血清α-突触核蛋白水平的平均值分别为3.60±2.53和0.03±0.04 pg/mL。血浆和血清α-突触核蛋白用于区分PD患者与健康对照的受试者工作特征曲线下面积分别为0.992和0.917。血清α-突触核蛋白水平在H-Y分期1-3期的患者中也显示出显著相关性（r = 0.40，P = 0.025），这意味着血清α-突触核蛋白水平可能是早期PD患者运动症状严重程度的潜在标志物。我们的数据表明，血清或血浆中的α-突触核蛋白水平可区分健康对照与PD患者。早期PD患者的血清α-突触核蛋白水平与运动严重程度中度相关。
